Singapore markets close in 4 hours 23 minutes
  • Straits Times Index

    3,249.52
    -2.85 (-0.09%)
     
  • Nikkei

    27,731.74
    -154.13 (-0.55%)
     
  • Hang Seng

    19,469.46
    +28.28 (+0.15%)
     
  • FTSE 100

    7,521.39
    -46.15 (-0.61%)
     
  • BTC-USD

    17,036.95
    +43.74 (+0.26%)
     
  • CMC Crypto 200

    402.12
    +0.32 (+0.08%)
     
  • S&P 500

    3,941.26
    -57.58 (-1.44%)
     
  • Dow

    33,596.34
    -350.76 (-1.03%)
     
  • Nasdaq

    11,014.89
    -225.05 (-2.00%)
     
  • Gold

    1,783.90
    +1.50 (+0.08%)
     
  • Crude Oil

    74.31
    +0.06 (+0.08%)
     
  • 10-Yr Bond

    3.5130
    -0.0860 (-2.39%)
     
  • FTSE Bursa Malaysia

    1,477.67
    +6.12 (+0.42%)
     
  • Jakarta Composite Index

    6,825.62
    -66.95 (-0.97%)
     
  • PSE Index

    6,649.08
    -25.30 (-0.38%)
     

Why Organogenesis Stock Is Tumbling Today

Shares of Organogenesis Holdings (NASDAQ: ORGO) fell by 19.6% as of 2:45 p.m. ET on Wednesday after the wound care company reported worse-than-anticipated Q2 earnings and also slashed its guidance for the rest of 2022. Its net revenue for the quarter was $121.4 million, a decline of 1% year over year, and its net income collapsed by 58% year over year to reach $8.7 million. For its fiscal 2022 earnings guidance, management now expects net revenue of between $465 million and $490 million, whereas in its initial guidance, it expected between $485 million and $515 million.